Titan Medical Inc. Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

EXPENSES BY NATURE

EXPENSES BY NATURE

12 Months Ended

Dec. 31, 2021

EXPENSES BY NATURE

19. EXPENSES BY NATURE

				Year ended December 31,
		2021				2020				2019
		$				$				$
R&D			32,197				7,937				51,418
Personnel costs			7,616				2,550				2,547
Professional and consulting			2,988				2,829				2,369
Share-based compensation			4,036				1,097				1,651
Public company and administrative			2,866				1,153				1,248
Severance charges			678				-				-
Total of R&D and G&A			50,381				15,566				59,233

Depreciation of right-of-use assets			304				105				4
Depreciation of property and equipment			152				35				-
Amortization of patent rights			243				143				29
Depreciation and amortization			699				283				33

Total expenses			51,080				15,849				59,266